Vascular remodeling and rearrangement of the extracellular matrix formation are among the major adaptive mechanisms in response to a chronic blood pressure increase. Vasoactive peptides, such as endothelin, participate in hypertension-associated vascular fibrosis by stimulating collagen I formation and increasing contractility of arterial wall. In the present study, we tested the hypothesis that activation of the epidermal growth factor (EGF) receptor pathway mediates these events. Experiments were performed in transgenic mice harboring the luciferase gene under the control of the collagen I-α2 chain promoter. Endothelin induced a rapid phosphorylation of the mitogen-activated protein kinase (MAPK)/ERK and increased collagen I gene activity in freshly isolated aortas. This effect of endothelin was totally inhibited by an endothelin receptor antagonist, an EGF receptor phosphorylation inhibitor, and a blocker of the MAPK/ERK cascade. In parallel experiments, inhibition of EGF receptor phosphorylation decreased the endothelin-induced pressor effect in isolated aortic rings and in anesthetized animals in vivo. In addition, the endothelin-induced increase of blood pressure was blunted in the waved-2 mice, a strain expressing functionally impaired EGF receptors. Our results provide the first evidence that the EGF receptor mediates at least two of the major actions of endothelin in the vascular tissue: contractility and fibrogenesis.
T he development of vascular fibrosis is one of the most common and important complications associated with hypertension. This pathophysiological process is characterized by structural changes and remodeling of the vascular wall mainly due to abnormal accumulation of extracellular matrix proteins such as collagen type I (1, 2) . Several studies in animals and humans have supported a key role for vasoconstrictor agents, such as angiotensin II (Ang II) and endothelin (ET-1), in the development of vascular fibrosis (3) . In particular, it is well established that inhibition or antagonism of Ang II or ET-1 slows the progression or even reverses vascular hypertrophy and fibrosis in several forms of hypertension (4, 5) . However, the signaling pathways used by these peptides to produce vascular fibrosis are unknown, and this area is a field of extensive investigation. Growing evidence implies that Ang II can activate the mitogen-activated protein kinase (MAPK) pathway and produce mitogenesis through activation of receptors such as epidermal growth factor (EGF) or platelet-derived growth factor (PDGF) receptors (6) . Although much less is known about the ability of ET-1 to stimulate such a pathway, it was recently reported that ET-1 induced transactivation of the EGF receptor and stimulated the MAPK pathway in cultured cardiomyocytes (7) .
In previous studies, we investigated the role of Ang II and ET-1 in the mechanisms of renal vascular fibrosis by using a strain of transgenic mice that express the luciferase reporter gene under the control of the promoter of the α2 chain of the collagen I gene [procolα2(I)]. Using this transgenic model, we observed that the pharmacological blockade of Ang II or ET-1 blunted the development of renal vascular fibrosis in experimental hypertension (nitric oxide deficiency model) by inhibiting collagen I gene activation (8, 9) . In these studies, it appeared that ET-1 was a key mediator of the Ang II-induced activation of the collagen I gene. In follow-up studies, we observed that the fibrogenic action of Ang II was also dependent on MAPK cascade activation (10) .
In the present studies, we investigated the role of EGF receptor activation in the two major actions of ET-1 on vascular wall contraction and remodeling. To this end, experiments were performed with the same strain of transgenic mouse that we have used elsewhere (8) (9) (10) to test the efficiency of pharmacological inhibitors of EGF receptor tyrosine kinase to block the ET-1-induced activation of collagen I gene and of vascular contractility. To address the latter issue, a mutant mouse strain was used that expresses low levels of functional EGF receptors (11) . Our observations are among the first to provide evidence of a key role for the EGF receptor in the vasoconstrictor and fibrogenic effects of ET-1.
MATERIALS AND METHODS

Animal strains
Male transgenic mice weighing 25-35 g (3-6 months old) at the time of the experiments were maintained on a normal-salt diet. Animals had free access to chow and tap water. Two strains of mice were used. The first transgenic line, pGB 19.5/13.5, was generated in the laboratory of B. de Crombrugghe (University of Texas, Houston) (12) . These animals harbor a construction containing the sequences -19.5 to -13.5 kb and -350 to +54 bp of the promoter of the α2 chain of mouse collagen type I gene linked to two reporter genes, the firefly luciferase, and the Escherichia coli β-galactosidase. The choice of these mice was based on previous studies showing that the expression pattern of the two reporter genes in embryos and adult animals closely correlates with tissue distribution (including aorta) of collagen I under physiological and/or pathological conditions (8, 9, 12) . In particular, we have found that acute administration of ET-1 stimulates in a similar way luciferase activity and mRNA expression for collagen I chains α1 and α2 in the aortic and renal cortical tissues (13) . The other mouse strain, waved-2, was provided by Dr. D. Lee (University of North Carolina, Chapel Hill) and was bred on the appropriate genetic background purchased from The Jackson Laboratory (Bar Harbor, ME). In this strain of animals, the EGF receptor is functionally operating at a level of ∼10% compared with normal mice (11) . The protocol followed the French Department of Agriculture and National Institutes of Health guidelines for animal care and protection.
Ex vivo addition of ET-1
Experiments were performed on freshly isolated thoracic aortas incubated in RPMI 1640 medium (containing 10 mmol HEPES, 2 mmol/l l L-glutamine, 100 U/ml penicillin, and 100 mg/l streptomycin) for up to 1 h at room temperature. The choice of the incubation temperature was based on preliminary experiments indicating that tissue luciferase activity remained stable at 22-25°C for at least 6 h. ET-1 (100 nM) was added either alone or in combination in tissues preincubated for 5 min with several inhibitors. PD98059 (50 µM) is a selective inhibitor of MEK. The concentration used is the same as that previously used in similar experimental conditions (10) . PD153035 (1 nM) and AG1478 (250 nM) are selective EGF receptor tyrosine kinase inhibitors. At these doses, AG1478 and PD153035 have no effect on other growth factor receptor kinases such as PDGF or fibroblastic growth factor (FGF) receptors. The overall incubation time is 90 min for the measurement of the luciferase activity and 10 min for the studies of MAPK/ERK and EGF receptor activation. In some control experiments, we used PDGF (10 ng/ml). Dissected tissues were immediately frozen and stored. ET-1, EGF, Ang II, and PDGF were obtained from Sigma (St. Louis, MO); PD98059, PD153035, and AG1478 were purchased from Calbiochem (LaJolla, CA). The inhibitors were initially dissolved in dimethyl sulfoxide as stock solutions and then in RPMI or saline for the ex vivo or in vivo experiments, respectively. In all cases, control experiments were performed with vehicle alone.
Assays for the expression of luciferase
Luciferase activity was measured using a commercial reporter gene assay kit (Boehringer Mannheim, Mannheim, Germany) and a Lumat LB 9507 luminometer (EG & Berthold, Paris France) as previously described (8) . Results are expressed as luciferase light units per µg of protein (LU/µg).
MAPK/ERK Western blot and activity assay
MAPK/ERK activity was assayed using Western blotting of phosphoERK with a selective antibody. In brief, the aortic segments were incubated in 400 µl of a lysis buffer containing Tris 10 mM (pH 7.4), NaCl 150 mM, EGTA 2 mM, DTT 2 mM, orthovanadate 1 mM, 4-(2-aminoethyl)-benzenesufonylfluoride HCl (AEBSF) 1mM, leupeptine 10µg/ml, and aprotinine 10 µg/ml. After brief homogenization, the tissues were centrifuged and aliquots of the supernatants were subjected to 7.5% sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Proteins in the gel were transferred to a PVDF membrane by electroblotting. The membrane was treated with the first antibodies (polyclonal antiphospho-p42-p44 MAPK antibody; dilution ratio, 1/5000; Promega, Madison, WI) and then with the second antibody (anti rabbit IgG HRP; dilution ratio, 1/5000; Amersham Pharmacia Biotech Buckinghamshire, England). After incubation, immunoreactive proteins were detected by an electrochemiluminescence (ECL) system (Amersham Pharmacia Biotech). In each case, a Western analysis was made with the same aliquots by using a first antibody detecting all forms, nonphosphorylated and phosphorylated of ERK1 and ERK2 (anti-ERK 1/2 pAb; dilution ratio, 1/5000; Promega). At last, the MAPK activity is estimated by the ratio of the optic signal density of phosphorylated vs. overall ERK. The results are expressed as percentage of the control value.
To better evaluate the activation of MAPK/ERK pathway, MAPK activity was also measured using a commercially available MAPK enzyme assay system (Cell Signaling, Beverly MA). This methodology gives estimates of MAPK activity by using the Elk-1 fusion protein as a substrate for the MAPKs. All steps were performed according to the manufacturer's instructions. For each sample, measurements of MAPK activity were made in duplicate.
Immunoblotting
Due to technical problems related to the amount of protein that could be extracted from mouse aorta, this series of experiments was performed in rat aortas. The aortic segments were lysed in 200 µl of a lysis buffer containing Tris 50 mM (pH 7.4), NaCl 150 mM, EDTA 1 mM, sodium deoxyclolate 0.25%, NaF 1 mM, orthovanadate 1 mM, protease cocktail inhibitor 1/100 (Calbiochem), and NP40 1%. After centrifugation, lysates (20 µg protein) were dissolved by the addition of Laemli buffer and subjected to immunoblotting. Thereafter, membranes were initially treated with rabbit polyclonal anti-phosphorylated form of EGFR (1/200; Santa Cruz Biotechnology, Santa Cruz, CA) or rabbit polyclonal anti-EGFR (1/200; Santa Cruz Biotechnology) antibodies, and then with secondary antibodies (1/5000); immunoreactive proteins were detected by the ECL system.
Analysis of the vascular reactivity of aortic ring segments
Ring segments of 5 mm in length were isolated from thoracic aortas and were mounted between two stainless steel wires in a 5 mL organ bath containing physiological salt solution (PSS) of the following composition: HEPES 10 mM (pH 7.4) containing NaCl 135 mM, NaHCO 3 15 mM, KCl 4.6 mM, CaCl 2 1.5 mM, MgSO 4 1.2 mM, and glucose 11 mM. The solution was bubbled with 95% O 2 /5%CO 2 . One wire was attached to a fixed support, and the second wire was connected to a moveable holder supporting a tension transducer so that isometric force measurements could be recorded on a physiograph (MP 100; Biopac Systems, La Jolla, CA). The aortic segments were allowed to recover for 60 min, and the PSS was replaced at 15-min intervals during this time. After this recovery period, a KCl load (125 mM), resulting in a maximal contraction, was applied to the aortic segments, which were then allowed to equilibrate for an additional 90 min. ET-1 (10 nM) was added to the bath solution alone or 10 min after addition of PD153035 (1 nM). The ET-1-induced isometric contraction of aortas is compared with that of KCl and the results are expressed as percentage of the KCl response. At the end of the experiment, the viability of the aortic rings was evaluated by a second analysis of KCLinduced contraction after an equilibration period of 60 min.
Acute administration of ET-1 and inhibitors of EGF receptor phosphorylation in vivo
ET-1 alone or combined with specific inhibitors of EGF receptor tyrosine kinase PD153035 and AG1478 were injected i.v. as boli of 100 µl in anesthetized mice through the caudal vein as previously described (13) . The choice of doses was based on previous experience (13) and on preliminary experiments.
Measurement of blood pressure
In the first series of experiments, systolic blood pressure was measured by the tail-cuff method adapted to the mouse as previously described (8, 13) . The outputs of the pressure transducer were interfaced to a data acquisition system composed of a computer and a MacLab/4s 16-bit analog to digital converter (ADInstruments, Castle Hill, Australia). Pressure recording was analyzed using the Chart module of the MacLab software. In the experiments with the waved-2, mice were anesthetized with an inhaled mixture of 95% O 2 /5%CO 2 and isoflurane 2%. No significant difference in weight was observed between homozygous waved-2 male mice and controls (28.42 ± 0.94 g vs. 29 .60 ± 0.92 g, respectively). The carotid artery and jugular vein were exposed and cannulated with polyethylene cannulas (PE-10, Becton Dickinson, Franklin Lakes, NJ) containing saline. Mean arterial pressure was measured through the carotid artery cannula connected to a pressure transducer. The jugular vein cannula was used for i.v. injections. Data were collected with the computer-assisted Acknowledge Workstation System (Biopac Systems). ET-1 was dissolved in sterile saline solution (0.9% NaCl; total volume, 50 µl) and injected through the jugular vein. The vehicle control was 50 µl saline. Hemodynamic parameters were recorded continuously for a minimum of 20 min after the injections.
Statistical methods
Results are expressed as mean ±SE. Statistical analyses were performed using ANOVA followed by protected least significance difference Fisher's test of the Statview software package. Results with P<0.05 were considered statistically significant.
RESULTS
Effect of EGF receptor inhibition on the ET-1-induced procolα2(I) gene activation
In agreement with our previous results (9, 13), endothelin administration induced an almost twofold increase of luciferase activity in freshly isolated aortas (185 ± 43 % vs. baseline, n=8, P<0.05; Fig. 1, upper panel) . To test whether EGF receptor activation was involved in the stimulatory effect of ET-1 on collagen I gene, we treated aortas with the specific EGF receptor inhibitor PD153035 before ET-1 administration. As shown in Figure 1 (upper panel), PD153035 completely blocked the increase of luciferase activity induced by ET-1 (115 ± 15% for ET-1 + PD153035, P<0.05 vs. ET-1, n=8). Administration of PD153035 alone had no effect on collagen I gene activity baseline (118 ± 15%).
Effect of MAPK/ERK inhibition on the ET-1-induced procolα2(I) gene activation
To determine whether the MAPK/ERK pathway was involved in this fibrogenic effect of ET-1, incubations were carried out in the presence of the specific inhibitor of the MAPK/ERK activation PD98059. As expected, ET-1 increased the luciferase activity in freshly isolated aortas (172% of baseline, or 3918 ± 779 vs. 2284 ± 748 RLU/µg for ET-1 and control, respectively, n=6, P<0.05; Fig. 1, lower panel) ; PD98059 completely blocked the stimulatory effect of ET-1 on procolα2(I) gene in aorta (95% of baseline, or 2152 ± 648 RLU/µg, P<0.05 vs. ET-1; n=6; Fig. 1, lower panel) . Administration of the PD98059 alone had no effect on the baseline of luciferase activity (90% of baseline, or 2019 ± 3 RLU/µg). This fibrogenic effect of ET-1 was also completely cancelled by bosentan, an ETA/B receptor antagonist (101% of control, or 2307 ± 512 RLU/µg)
ET-1-induced activation of the MAPK/ERK pathway
Next, we verified whether ET-1 activated the MAPK/ERK cascade in our protocol by performing Western blot analysis in freshly isolated mouse aortas. As shown in Figure 2A , and in agreement with the literature, ET-1 produced a twofold increase of MAPK activity (223 ± 51% vs. control, P<0,01, n=7). This effect was totally blocked by pretreatment with the MAPK/ERK inhibitor PD98059 (50 µM) (90 ± 10%; P<0.01 vs. ET-1, Fig. 2 ). PD98059 alone had no effect on MAPK activity baseline (104 ± 6%).
In a series of additional experiments, this ET-1-induced activation of the MAPK pathway was cancelled by the dual ETA/B receptor antagonist, bosentan (191 ± 32 vs. 118 ± 45% of baseline for ET-1 alone or in presence of bosentan, respectively, P<0.05, n=5, Fig. 2B ).
EGF receptor as mediator of the ET-1-induced activation of the MAPK/ERK
To examine whether EGFR tyrosine kinase was involved in the interaction between ET-1 and MAPK, we tested first whether the EGF receptor was phosphorylated after stimulation of aortic segments with ET-1. As shown by immunoblot analysis (Fig. 3A) , ET-1 (100 nM) induced a rapid phosphorylation of the EGF receptor to a level similar to that induced by 50 ng of EGF.
Next, we investigated whether the ET-1-induced activation of EFG receptor was involved in the activation of the MAPK pathway. As shown in Figure 3B , the ET-1-induced activation of MAPK (184 ± 51% vs. control, P<0.05, n=6) was completely cancelled when aortic fragments were pretreated with the specific inhibitor of the EGF receptor phosphorylation PD153035 (1 nM) (92 ± 33% for PD153035 + ET-1, P<0.05 vs. ET-1, n=6). Similar results were obtained when MAPK activation was measured using a p44/42 MAPK assay; this assay is based on the degree of phosphorylation of Elk-1 (Fig. 3C) . We have also checked whether the inhibitory effect of PD153035 was specific to EGF. To this end, aortic segments were stimulated by EGF or PDGF in the presence or absence of PD153035. The EGF receptor inhibitor reduced the EGF-induced phosphorylation of ERK1/2, whereas it had no effect on the PDGF-induced phosphorylation of ERK1/2 (data not shown).
Involvement of EGF receptor in the ET-1-induced aortic contraction
Addition of ET-1 in aortic ring segments increased vascular wall tension to 35% of the KClinduced contraction (Fig. 4) . This constrictor effect of ET-1 was markedly reduced when PD153035 was applied to aortic rings before ET-1 (34 ± 15 vs. 10 ± 10% of the KCl-induced aortic contraction for ET-1 and ET-1 + PD153035, respectively, P<0.05, n=6; Fig. 4, lower  panel) . The fact that the contractile response to KCl (125 mM) remained the same throughout the experiment (100 ± 15 vs. 100 ± 12% for the beginning and the end of the experiments, respectively, n=6) eliminates the possibility of a toxic effect of PD153035 on the aortic rings.
Effect of EGF receptor inhibition on the ET-1-induced systolic pressure increase
This set of experiments was performed to test whether the EGF receptor activation participates in the in vivo ET-1-induced pressor effect. To this end, ET-1 alone or mixed with PD153035 or AG1478 (another specific inhibitor of EGF receptor tyrosine kinase that is chemically different from PD153035) was administered i.v. in anesthetized animals. As expected, ET-1 produced a strong and sustained (20-25 min) increase of blood pressure (Fig. 5A, left) ; interestingly, this pressor effect of ET-1 was cancelled in the presence of PD153035 (Fig. 5A, right) . The ET-1-induced increase of systolic pressure averaged 39 ± 14 mmHg above baseline when injected alone (P<0.01 vs. control; Fig. 5A , lower panel), whereas it was reduced to 10 ± 7 mmHg when injected in the presence of PD153035 (Fig. 5A, lower panel; P<0.01 vs. ET-1 alone). Administration of PD153035 alone had no effect on blood pressure (5 ± 6 mmHg, Fig. 5A ). Similar recordings were obtained with the other EGF receptor inhibitor, AG1478 (46 ± 12, 3 ± 4, and -2 ± 3 mmHg for ET-1 alone, ET-1 mixed with AG1478, or AG1478 alone, respectively).
We further investigated the ability of the EGF receptor tyrosine kinase inhibition to reduce the sustained effect of ET-1-induced vasoconstriction. To this end, PD153035 was injected 5 min following ET-1 administration. As shown in Figure 5B , ET-1 increased the systolic pressure from 80 ± 15 to 137 ± 12 mmHg (P<0.01, n=5) and this increase was reduced to 84 ± 10 mmHg after injection of PD153035 (P<0.01 vs. ET-1, n=5).
ET-1-induced increase of blood pressure in genetically malfunctioning EGF receptor
To confirm the role of EGF receptor activation as mediator of the pressor effect of ET-1, we used waved-2 mice, a strain of mice carrying a mutation in the EGF receptor; this mutation is responsible for a reduced response to the EGF-induced stimulation of tyrosine kinase activity (∼10% of the control). No difference was observed in body weight or in mean arterial pressure baseline between anesthetized waved-2 and wild-type controls (body weight: 28.42 ± 0.94 vs. 29.60 ± 0.92 g; blood pressure: 98 ± 5 vs. 100 ± 4 mmHg, for waved-2 and controls, respectively). Bolus injection of ET-1 (80 pmol) produced a weak increase in systolic pressure (11 ± 2 mmHg) in waved-2 mice, whereas the same dose of ET-1 increased systolic pressure by 34 ± 17 mmHg in the wild-type control mice (P<0.05, n=5 and 8 for waved-2 and controls, respectively, Fig. 6) .
DISCUSSION
]In the present study, using complementary ex vivo and in vivo approaches and two different strains of genetically modified animals, we observed that the activation of EGF receptor mediates the fibrogenic and contractile actions of ET-1. In particular, we found that the ET-1-induced activation of collagen I gene was dependent on EGF receptor and MAPK activation and that pharmacological inhibition of EGF receptor phosphorylation prevented this fibrogenic effect of ET-1. In addition, pharmacological blockade of EGF receptor activation blunted the vasoconstrictor action of ET-1 in isolated aortic rings and in anesthetized animals as well. The involvement of EGF receptor as a mediator of the ET-1 pressor response was further confirmed in genetically altered mice displaying a truncated response to EGF-induced tyrosine kinase activation.
Several recent studies have established a major role for ET-1 in the development of vascular fibrosis. For instance, endothelin displayed mitogenic properties and induced protein synthesis (particularly collagen I) in cultured vascular, coronary smooth muscle, or mesangial cells (14) (15) (16) (17) , whereas endothelin antagonism was accompanied by reversal of vascular hypertrophy in the DOCA-salt-, angiotensin II-, or L-NAME-induced hypertension in the rat in vivo (18) (19) (20) . In addition, in a murine model of lupus nephritis, endothelin receptor antagonism improved renal structural damage and reduced extracellular matrix, including collagen I, III, IV and laminin and proteoglycan formation (21) , whereas transgenic mice overexpressing human endothelin 1 gene develop renal vascular damage, glomerulosclerosis, and interstitial fibrosis (22) .
In agreement with this notion, we have previously reported that pharmacological blockade of ET-1 action prevented the development of vascular and renal fibrosis during experimental hypertension by inhibiting the activation of collagen I gene (8) . In addition, we have observed that acute administration of ET-1 in aortic segments or in renal cortical slices was accompanied by a rapid increase of collagen I gene expression (13) . The present studies confirm these previous results and further extend the mechanism of fibrogenic action of ET-1 by implying the involvement of the MAPK pathway. Addition of ET-1 was accompanied by a rapid phosphorylation of MAPK/ERK and an increase of procol1α (2) activity (Figs. 1 and 2) ; inversely, inhibition of MAPK/ERK phosphorylation cancelled the ET-1-induced activation of collagen I gene (Fig. 1 ). An ET-1-induced activation of the MAPK/ERK pathway has been previously observed in cultured smooth muscle or mesangial cells and in aortic tissue in vitro (23) (24) (25) . Our study is among the first to show that this activation of the MAPK cascade is involved in the fibrogenic action of ET-1 in the vascular wall.
Recently, a novel notion has emerged that the activation of growth factor receptors may mediate trophic effects of vasoactive agents. For instance, it appears that Ang II activates the MAPK cascade to produce hypertrophy and mitogenesis in cultured smooth muscle or mesangial cells through EGF or PDGF receptor transactivation (6) . A similar mechanism has been suggested for ET-1. For instance, ET-1 failed to activate MAPK cascade in a line of neuroepithelial cells (SK-N-MC) that do not express the EGF receptor; when these cells were transfected with the EGF receptor, ET-1 induced phosphorylation of MAPK (26) . The mechanism of interaction between vasoactive peptides and EGF receptor remains a matter of controversy. Initial investigations supported the hypothesis of an intracellular way of transactivation in which EGF ligands are not involved (27) . In this regard, the Ang II-induced transactivation of EGF receptor was not inhibited by the presence of an anti-EGF antibody (28) . However, this notion was challenged by investigations proposing that the transactivation of EGF receptor can be induced by its endogenous ligand HB-EGF, which is activated following enzymatic cleavage by a metalloproteinase (29) . Supporting this hypothesis, specific blockade of metalloprotease 12 inhibited the transactivation of EGF receptor and attenuated the development of cardiac hypertrophy in mice (30) . Regardless of the cellular mechanism, in our experiments, addition of ET-1 in freshly isolated aortas induced a rapid phosphorylation of the EGF receptor, similar to that observed by the EGF itself (Fig. 3) .
The interaction between ET-1 and EGF receptor to produce mitogenesis and cell proliferation is well established in the literature (27, 31) . Less known is whether this interaction is involved in the fibrotic effects of ET-1. Recently, it has been reported that endothelin mediates vascular growth in cultured smooth muscle cells by transactivating the EGF receptor, which in turn activates the MAPK pathway (32) . A novel finding of our study is that the ET-1/EGF receptor/MAPK interaction participates in the fibrogenic effect of ET-1. The pharmacological blockade of EGF receptor phosphorylation cancelled the ET-1-induced activation of MAPK and collagen I gene (Figs. 1 and 3) . It would be interesting in future studies to test whether a similar interaction exists in pathological conditions and whether pharmacological blockers of the EGF receptor could be used to prevent vascular fibrosis.
Another important novel finding of our study is that EGF receptor activation is a major mediator of the vasoconstrictor effect of ET-1. This finding was corroborated by three different complementary observations: pharmacological blockade of the EGF receptor activation completely inhibited the ET-1-induced increase of vascular wall tension in aortas ex vivo (Fig.  4) , pharmacological blockade of the EGF receptor activation prevented and/or reversed the ET-1-induced blood pressure increase in normal animals in vivo (Fig. 5) , and the ET-1 pressor effect was substantially reduced in mutant animals with impaired EGF receptor function (Fig. 6 ). To date, few studies have examined the role of EGF receptor in the vasoconstrictor action of peptides such as Ang II or ET-1. An initial report observed that exogenous EGF increased the Ang II-induced contractility in isolated pulmonary arteries (33) . It was also reported that EGF shared a similar pathway to that of Ang II to produce contraction of aortic rings (34) . However, other investigators observed that two EGF receptor ligands (EGF and TGFα) did not produced any contractile response when applied in aortas isolated from normotensive controls (35) . Interestingly, a proper vasoconstrictor action of EGF was observed in aortas isolated from hypertensive animals in which Ang II or ET-1 play an important role, such as the DOCA-salt, L-NAME, or SHR models (35, 36) . In addition, this abnormal reactivity in aortas of DOCA-salttreated animals was not due to an increased expression of EGF receptors but to an enhanced activation of signaling (37) . It is thus possible, that the role of EGF receptor as a mediator of vasoconstriction depends on the physiopathological context of the vascular wall: Under normal conditions, its involvement appears to be negligible; in contrast, the transactivation of EGF receptor appears to become an important factor of vascular contractility in pathologies associated with activation of the endothelin or the renin-angiotensin systems.
In conclusion, this study provides new information about the mechanisms by which endothelin promotes fibrogenesis and contraction within the vascular wall. The ET-1-induced activation of collagen I gene depends on MAPK activation, which is at least partly due to EGF receptor transactivation. In addition, the EGF receptor transactivation contributes to the ET-1-induced vasoconstriction. Thus, a single cellular phenomenon, EGF receptor activation, appears to mediate the acute fibrotic and vasomotor effects of a potent vasoconstrictor such as endothelin. This observation opens new perspectives about the role of EGF receptor and the eventual use of its inhibitors in cardiovascular or hypertensive diseases. 
